Retrieve available abstracts of 163 articles: HTML format
Single Articles
August 2025
LUO YS, Shen H, Ling P, Gao H, et al Tirofiban protects mice against severe RSV pneumonia by potentially inhibiting
platelet activation via the GPIbalpha-vWF pathway.
Antiviral Res. 2025;240:106207. PubMedAbstract available
June 2025
HUSSAIN S, Meijer A, Govorkova EA, Dapat C, et al Global update on the susceptibilities of influenza viruses to neuraminidase
inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.
Antiviral Res. 2025 Jun 24:106217. doi: 10.1016/j.antiviral.2025.106217. PubMedAbstract available
MARTINEZ-GZEGOZEWSKA Y, Rasmussen L, Nebane NM, McKellip S, et al High-throughput screening for identification of Influenza A inhibitors using a
cell-based immunofluorescence assay.
Antiviral Res. 2025 Jun 6:106209. doi: 10.1016/j.antiviral.2025.106209. PubMedAbstract available
MALUNE P, Esposito F, Tramontano E Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2
RNA-dependent RNA polymerase.
Antiviral Res. 2025 Jun 3:106208. doi: 10.1016/j.antiviral.2025.106208. PubMedAbstract available
May 2025
FAGE C, Loison S, Zwygart AC, Poli R, et al Influenza A(H1N1)pdm09 Virus Resistance to Baloxavir, Oseltamivir and Sialic Acid
Mimetics in Single and Dual therapies: Insights from Human Airway Epithelia and
Murine Models.
Antiviral Res. 2025 May 3:106174. doi: 10.1016/j.antiviral.2025.106174. PubMedAbstract available
TAKASHITA E, Yasui Y, Ikegaya A, Saka K, et al Impact of the Polymerase Acidic Protein E199K Substitution in Influenza A Viruses
on Baloxavir Susceptibility.
Antiviral Res. 2025 May 3:106173. doi: 10.1016/j.antiviral.2025.106173. PubMedAbstract available
BONNEUX B, Ceconi M, Stobbelaar K, Herschke F, et al Insights in the RSV L polymerase function and structure.
Antiviral Res. 2025;237:106148. PubMedAbstract available
March 2025
ZHU Y, Gao Z, Feng X, Hu Y, et al Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion
inhibitor under clinical trials.
Antiviral Res. 2025;237:106154. PubMedAbstract available
KUO YS, Chiang PC, Kuo CY, Huang CG, et al Inhibition of influenza A virus proliferation in mice via universal RNA
interference.
Antiviral Res. 2025 Mar 25:106149. doi: 10.1016/j.antiviral.2025.106149. PubMedAbstract available
PADEY B, Droillard C, Duliere V, Fouret J, et al Host-targeted repurposed diltiazem enhances the antiviral activity of direct
acting antivirals against Influenza A virus and SARS-CoV-2.
Antiviral Res. 2025 Mar 4:106138. doi: 10.1016/j.antiviral.2025.106138. PubMedAbstract available
February 2025
BRUN J, Arman BY, Hill ML, Kiappes JL, et al Assessment of repurposed compounds against coronaviruses highlights the antiviral
broad-spectrum activity of host-targeting iminosugars and confirms the activity
of potent directly acting antivirals.
Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123. PubMedAbstract available
ZIAN D, Iaconis D, Nenci S, Crusco A, et al The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis
during medical emergencies: identification of effective antiviral 3CLpro
inhibitors.
Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119. PubMedAbstract available
INOUE A, Ichikawa T, Wada D, Maruyama S, et al M49L and other drug resistance mutations emerging in individuals after
administration of ensitrelvir in Japanese clinical settings.
Antiviral Res. 2025;236:106118. PubMedAbstract available
TIETJEN I, Kwan DC, Petrich A, Zell R, et al Antiviral Mechanisms and Preclinical Evaluation of Amantadine Analogs that
Continue to Inhibit Influenza A Viruses with M2(S31N)-Based Drug Resistance.
Antiviral Res. 2025 Feb 11:106104. doi: 10.1016/j.antiviral.2025.106104. PubMedAbstract available
SCHREIBER A, Ludwig S Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or
disappointment?
Antiviral Res. 2025;235:106101. PubMedAbstract available
January 2025
UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro)
detected in the SCORPIO-SR phase 3 trial.
Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097. PubMedAbstract available
WU Q, Wu H, Hu Y, Zheng X, et al Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and
monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
Antiviral Res. 2025 Jan 24:106092. doi: 10.1016/j.antiviral.2025.106092. PubMedAbstract available
XU M, Zhang Z, Sun Y, Mai H, et al IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased
antibody hinge flexibility.
Antiviral Res. 2025 Jan 17:106082. doi: 10.1016/j.antiviral.2025.106082. PubMedAbstract available
MAIA AR, Gonzalez L, Bounab B, Grassi L, et al Intranasal exposure to commensal bacterium Rothia mucilaginosa protects against
influenza A virus infection.
Antiviral Res. 2025 Jan 2:106076. doi: 10.1016/j.antiviral.2025.106076. PubMedAbstract available
December 2024
GAO M, Zhang Z, Yao G, Zhang L, et al Design, synthesis, and biological evaluation of novel
2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2
agents.
Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060. PubMedAbstract available
MERCURI FA, Anderson GP, Miller BE, Demaison C, et al Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of
complications resulting from viral respiratory infections.
Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063. PubMedAbstract available
SHANNON A, Canard B Nucleotide analogues and mpox: Repurposing the repurposable.
Antiviral Res. 2024;234:106057. PubMedAbstract available
WANG B, Xia H, Peng BH, Choi EJ, et al Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease
severity.
Antiviral Res. 2024;233:106059. PubMedAbstract available
SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral
activity of 4'-fluorouridine.
Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046. PubMedAbstract available
WELCH SR, Bilello JP, Carter K, Delang L, et al Meeting report of the 37th International Conference on Antiviral Research in Gold
Coast, Australia, May 20-24, 2024, organized by the International Society for
Antiviral Research.
Antiviral Res. 2024;232:106037. PubMedAbstract available
November 2024
AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al Preventing human influenza and coronaviral mono or coinfection by blocking
virus-induced sialylation.
Antiviral Res. 2024;232:106041. PubMedAbstract available
SRIWILAIJAROEN N, Hanamatsu H, Yokota I, Nishikaze T, et al Edible bird's nest: N- and O-glycan analysis and synergistic anti-avian influenza
virus activity with neuraminidase inhibitors.
Antiviral Res. 2024 Nov 20:106040. doi: 10.1016/j.antiviral.2024.106040. PubMedAbstract available
MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro)
inhibitor with pan-coronavirus activity.
Antiviral Res. 2024;232:106038. PubMedAbstract available
SASAKI J, Sato A, Sasaki M, Okabe I, et al X-206 exhibits broad-spectrum anti-beta-coronavirus activity, covering SARS-CoV-2
variants and drug-resistant isolates.
Antiviral Res. 2024 Nov 19:106039. doi: 10.1016/j.antiviral.2024.106039. PubMedAbstract available
ZHANG W, Lin X, Li ZY, Zhang LJ, et al Novel intercellular spread mode of respiratory syncytial virus contributes to
neutralization escape.
Antiviral Res. 2024;231:106023. PubMedAbstract available
ZHANG K, Yang XM, Sun H, Cheng ZS, et al Modulating apoptosis as a novel therapeutic strategy against Respiratory
Syncytial Virus infection: insights from Rotenone.
Antiviral Res. 2024;231:106007. PubMedAbstract available
RICHTER M, Khrenova M, Kazakova E, Riabova O, et al Dynamic features of virus protein 1 and substitutions in the 3-phenyl ring
determine the potency and broad-spectrum activity of capsid-binding
pyrazolo[3,4-d]pyrimidines against rhinoviruses.
Antiviral Res. 2024;231:105993. PubMedAbstract available
October 2024
NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and
infection in a hamster aerosol transmission model.
Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026. PubMedAbstract available
LO CW, Kariv O, Hao C, Gammeltoft KA, et al Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to
Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon System.
Antiviral Res. 2024 Oct 16:106022. doi: 10.1016/j.antiviral.2024.106022. PubMedAbstract available
September 2024
VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al Large-scale deep learning identifies the antiviral potential of PKI-179 and
MTI-31 against coronaviruses.
Antiviral Res. 2024;231:106012. PubMedAbstract available
HERRMANN A, Gege C, Wangen C, Wagner S, et al Orally Bioavailable RORgamma/DHODH Dual Host-Targeting Small Molecules with
Broad-Spectrum Antiviral Activity.
Antiviral Res. 2024 Sep 19:106008. doi: 10.1016/j.antiviral.2024.106008. PubMedAbstract available
KUMAR P, Zhang X, Shaha R, Kschischo M, et al Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine
mutagenesis.
Antiviral Res. 2024;231:106006. PubMedAbstract available
DO TND, Abdelnabi R, Boda B, Constant S, et al The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is
highly efficient in inhibiting coronavirus replication in human nasal airway
epithelial cell cultures and in a hamster infection model.
Antiviral Res. 2024 Sep 3:105994. doi: 10.1016/j.antiviral.2024.105994. PubMedAbstract available
BONNEUX B, Jacoby E, Ceconi M, Stobbelaar K, et al Direct-acting antivirals for RSV treatment, a review.
Antiviral Res. 2024;229:105948. PubMedAbstract available
August 2024
YAMASAKI M, Saso W, Yamamoto T, Sato M, et al Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease
region of viral RNA.
Antiviral Res. 2024;230:105992. PubMedAbstract available
LEE P, Kim J, Oh H, Kim CU, et al Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against
Hetero-species Coronavirus in Murine Models.
Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991. PubMedAbstract available
CONG Y, Dixit S, Perry DL, Huzella LM, et al Characterization of therapeutic antibodies efficacy against multiple SARS-CoV-2
variants in the hamster model.
Antiviral Res. 2024 Aug 13:105987. doi: 10.1016/j.antiviral.2024.105987. PubMedAbstract available
BONOMINI A, Zhang J, Ju H, Zago A, et al Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with
oseltamivir against human and avian influenza viruses in cell culture and in ovo.
Antiviral Res. 2024 Aug 6:105980. doi: 10.1016/j.antiviral.2024.105980. PubMedAbstract available
HAN Z, Mai Q, Zhao Y, Liu X, et al Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses
against homologous and heterologous influenza viruses.
Antiviral Res. 2024 Aug 6:105978. doi: 10.1016/j.antiviral.2024.105978. PubMedAbstract available
KEISER PT, Zhang W, Ricca M, Wacquiez A, et al Amidino-Rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors
of SARS-CoV-2 replication through inhibition of viral protein synthesis.
Antiviral Res. 2024 Aug 6:105976. doi: 10.1016/j.antiviral.2024.105976. PubMedAbstract available
YOON KW, Chu KB, Eom GD, Mao J, et al Orally Dissolving Film as a Potential Vaccine Delivery Carrier to Prevent
Influenza Virus Infection.
Antiviral Res. 2024 Aug 5:105979. doi: 10.1016/j.antiviral.2024.105979. PubMedAbstract available
July 2024
ROSALES R, McGovern BL, Rodriguez ML, Leiva-Rebollo R, et al Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral
activity against circulating SARS-CoV-2 Omicron subvariants.
Antiviral Res. 2024 Jul 25:105970. doi: 10.1016/j.antiviral.2024.105970. PubMedAbstract available
OLIVEIRA EH, Monteleone-Cassiano AC, Tavares L, Santos JC, et al A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases
pulmonary inflammation related to COVID-19.
Antiviral Res. 2024;229:105968. PubMedAbstract available
CHEN D, Su W, Choy KT, Chu YS, et al High throughput profiling identified PA-L106R amino acid substitution in
A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in
vitro.
Antiviral Res. 2024 Jul 11:105961. doi: 10.1016/j.antiviral.2024.105961. PubMedAbstract available
ANDREEV K, Jones JC, Seiler P, Kandeil A, et al Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to
neuraminidase and cap-dependent endonuclease inhibitors.
Antiviral Res. 2024 Jul 8:105959. doi: 10.1016/j.antiviral.2024.105959. PubMedAbstract available
XU Y, Sun F, Chuai Z, Wang J, et al Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial
virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats
against RSV infection.
Antiviral Res. 2024 Jul 8:105960. doi: 10.1016/j.antiviral.2024.105960. PubMedAbstract available
YOTSUYANAGI H, Ohmagari N, Doi Y, Yamato M, et al Prevention of Post COVID-19 Condition by Early Treatment with Ensitrelvir in the
Phase 3 SCORPIO-SR Trial.
Antiviral Res. 2024 Jul 5:105958. doi: 10.1016/j.antiviral.2024.105958. PubMedAbstract available
CHON I, Wagatsuma K, Saito R, Tang JW, et al Detection of influenza A(H3N2) viruses with polymerase acidic subunit
substitutions after and prior to baloxavir marboxil treatment during the
2022-2023 influenza season in Japan.
Antiviral Res. 2024 Jul 3:105956. doi: 10.1016/j.antiviral.2024.105956. PubMedAbstract available
JI J, Tang T, Zhu M, Wu Z, et al Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex
adjuvant.
Antiviral Res. 2024 Jul 2:105954. doi: 10.1016/j.antiviral.2024.105954. PubMedAbstract available
BONNEUX B, Shareef A, Tcherniuk S, Anson B, et al JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain
of the viral polymerase.
Antiviral Res. 2024;227:105907. PubMedAbstract available
June 2024
WILLIAMS N, Silva F, Schmolke M Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral
therapy.
Antiviral Res. 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951. PubMedAbstract available
LV L, Yang X, Zhang Y, Ren X, et al hnRNPAB inhibits Influenza A virus infection by disturbing polymerase activity.
Antiviral Res. 2024;228:105925. PubMedAbstract available
DANIELS A, Padariya M, Fletcher S, Ball K, et al Molecules targeting a novel homotrimer cavity of Spike protein attenuate
replication of SARS-CoV-2.
Antiviral Res. 2024;228:105949. PubMedAbstract available
BALIGA-GIL A, Soszynska-Jozwiak M, Ruszkowska A, Szczesniak I, et al Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2
replication.
Antiviral Res. 2024 Jun 24:105946. doi: 10.1016/j.antiviral.2024.105946. PubMedAbstract available
LIU X, Zheng M, Zhang H, Feng B, et al Characterization and noncovalent inhibition of the K63-deubiquitinase activity of
SARS-CoV-2 PLpro.
Antiviral Res. 2024 Jun 22:105944. doi: 10.1016/j.antiviral.2024.105944. PubMedAbstract available
DICKEY TH, Salinas ND, Patel P, Orr-Gonzalez S, et al RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike
vaccination.
Antiviral Res. 2024 Jun 18:105937. doi: 10.1016/j.antiviral.2024.105937. PubMedAbstract available
SUN Y, Wagatsuma K, Saito R, Sato I, et al Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B
virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir
in Japan during the 2012-2013 and 2019-2020 influenza seasons.
Antiviral Res. 2024 Jun 17:105938. doi: 10.1016/j.antiviral.2024.105938. PubMedAbstract available
ZHAI G, Fu W, Yuan S, Sun P, et al A fusion protein approach to integrate antiviral and anti-inflammatory activities
for developing new therapeutics against influenza A virus infection.
Antiviral Res. 2024 Jun 9:105924. doi: 10.1016/j.antiviral.2024.105924. PubMedAbstract available
LI J, Cui H, Yao Y, Niu J, et al Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2.
Antiviral Res. 2024 Jun 6:105919. doi: 10.1016/j.antiviral.2024.105919. PubMedAbstract available
GUO M, Peng J, Guo P, Wang Q, et al Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory
syncytial virus infection in mice.
Antiviral Res. 2024;226:105880. PubMedAbstract available
May 2024
VAN LOY B, Stevaert A, Naesens L The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent
antiviral drug target.
Antiviral Res. 2024 May 31:105921. doi: 10.1016/j.antiviral.2024.105921. PubMedAbstract available
LE UNP, Chang YJ, Lu CH, Chen Y, et al Glycyrrhizic acid conjugates with amino acid methyl esters target the main
protease, exhibiting antiviral activity against wild-type and
nirmatrelvir-resistant SARS-CoV-2 variants.
Antiviral Res. 2024;227:105920. PubMedAbstract available
FRANCO-MAY DA, Gomez-Carballo J, Barrera-Badillo G, Cruz-Ortiz MN, et al Low antiviral resistance in Influenza A and B viruses isolated in Mexico from
2010 to 2023.
Antiviral Res. 2024;227:105918. PubMedAbstract available
LIANG Y, Xiao W, Peng Y, Zhang S, et al Development of Nanoparticle Vaccines Utilizing Designed Fc-Binding Homo-oligomers
and RBD-Fc of SARS-CoV-2.
Antiviral Res. 2024 May 21:105917. doi: 10.1016/j.antiviral.2024.105917. PubMedAbstract available
HUANG J, Wang W, Li H, Bai Y, et al Three in one: An effective and universal vaccine expressing heterologous tandem
RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
Antiviral Res. 2024;227:105905. PubMedAbstract available
PANDEY K, Acharya A, Pal D, Jain P, et al SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor,
Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity
against the Omicron variant of SARS-CoV-2.
Antiviral Res. 2024;227:105904. PubMedAbstract available
SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile
and practical infection model for antiviral research and beyond.
Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903. PubMedAbstract available
April 2024
LIU X, Wang Y, Sun L, Xiao G, et al Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898. PubMedAbstract available
ARDUINO I, Francese R, Civra A, Feyles E, et al Polyoxometalate exerts broad-spectrum activity against human respiratory viruses
hampering viral entry.
Antiviral Res. 2024;226:105897. PubMedAbstract available
AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and
first-generation COVID-19 vaccines: Is there a future therapeutic role for
soluble ACE2 receptors for COVID-19?
Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894. PubMedAbstract available
GLITSCHER M, Benz NI, Sabino C, Murra RO, et al Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate
immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
Antiviral Res. 2024;226:105891. PubMedAbstract available
TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al Development of a highly stable, active small interfering RNA with broad activity
against SARS-CoV viruses.
Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879. PubMedAbstract available
March 2024
RAHA JR, Kim KH, Bhatnagar N, Liu R, et al Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2
ectodomain virus-like particle improves protection against homologous and
heterologous influenza viruses in aged mice.
Antiviral Res. 2024;225:105877. PubMedAbstract available
KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
Antiviral Res. 2024;225:105874. PubMedAbstract available
SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in
vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871. PubMedAbstract available
PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor
N-0385 and synergistic action with direct-acting antivirals.
Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869. PubMedAbstract available
MOON C, Porges E, Roberts A, Bacon J, et al A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2
replication.
Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859. PubMedAbstract available
BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses
in their differential inflammasome activating potential.
Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857. PubMedAbstract available
WANG W, Wang S, Meng X, Zhao Y, et al A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing
technology elicits broad-spectrum protection against SARS-CoV-2.
Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854. PubMedAbstract available
KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights
into the mode-of-action of Concanavalin A.
Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856. PubMedAbstract available
SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the
development of SARS-CoV-2 resistance.
Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840. PubMedAbstract available
February 2024
GOTO T, Kawai N, Bando T, Takasaki Y, et al Virological and clinical outcomes in outpatients treated with baloxavir or
neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the
2022-2023 season.
Antiviral Res. 2024;224:105853. PubMedAbstract available
NOBORI H, Baba K, Kuroda T, Baba K, et al Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Antiviral Res. 2024;224:105852. PubMedAbstract available
LI H, Sun M, Lei F, Liu J, et al Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a
potential candidate against SARS-cov-2 infection.
Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841. PubMedAbstract available
BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against
SARS-CoV-2 and enveloped viruses.
Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837. PubMedAbstract available
ZHANG X, Xia Y, Li P, Wu Z, et al Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A
virus.
Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822. PubMedAbstract available
SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al Unmasking the potential of secretory IgA and its pivotal role in protection from
respiratory viruses.
Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823. PubMedAbstract available
IZMAILYAN R, Matevosyan M, Khachatryan H, Shavina A, et al Discovery of new antiviral agents through artificial intelligence: In vitro and
in vivo results.
Antiviral Res. 2024;222:105818. PubMedAbstract available
RICHTER M, Doring K, Blaas D, Riabova O, et al Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine
capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket:
Derivatives that brake resistance.
Antiviral Res. 2024;222:105810. PubMedAbstract available
LOAIZA RA, Ramirez RA, Sepulveda-Alfaro J, Ramirez MA, et al A molecular perspective for the development of antibodies against the human
respiratory syncytial virus.
Antiviral Res. 2024;222:105783. PubMedAbstract available
January 2024
WINIGER RR, Perez L Therapeutic antibodies and alternative formats against SARS-CoV-2.
Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820. PubMedAbstract available
BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814. PubMedAbstract available
BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813. PubMedAbstract available
IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al An intranasally delivered ultra-conserved siRNA prophylactically represses
SARS-CoV-2 infection in the lung and nasal cavity.
Antiviral Res. 2024;222:105815. PubMedAbstract available
MATTHYS A, Saelens X Promises and challenges of single-domain antibodies to control influenza.
Antiviral Res. 2024 Jan 12:105807. doi: 10.1016/j.antiviral.2024.105807. PubMedAbstract available
GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower
inflammatory consequences.
Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806. PubMedAbstract available
ZOU G, Cao S, Gao Z, Yie J, et al Current state and challenges in respiratory syncytial virus drug discovery and
development.
Antiviral Res. 2024;221:105791. PubMedAbstract available
December 2023
CHEN X, Tian L, Zhang L, Gao W, et al Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and
stabilizing the envelope protein.
Antiviral Res. 2023;221:105790. PubMedAbstract available
SUN X, Ma H, Wang X, Bao Z, et al Broadly neutralizing antibodies to combat influenza virus infection.
Antiviral Res. 2023 Dec 23:105785. doi: 10.1016/j.antiviral.2023.105785. PubMedAbstract available
AKSU M, Kumar P, Guttler T, Taxer W, et al Nanobodies to multiple spike variants and inhalation of nanobody-containing
aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778. PubMedAbstract available
ZUR M, Peselev T, Yanko S, Rotshild V, et al Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients:
Systematic review and network meta-analysis.
Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768. PubMedAbstract available
November 2023
WANG S, Cui H, Zhang C, Li W, et al Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and
broad-spectrum protection against SARS-CoV-2 variants of concern in golden
hamsters.
Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765. PubMedAbstract available
GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved
in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2
infection.
Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760. PubMedAbstract available
WU CY, Tseng YC, Kao SE, Wu LY, et al Monoglycosylated SARS-CoV-2 receptor binding domain fused with
HA(stem)-scaffolded protein vaccine confers broad protective immunity against
SARS-CoV-2 and influenza viruses.
Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759. PubMedAbstract available
ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron
by intranasal immunization.
Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757. PubMedAbstract available
SADHU S, Dandotiya J, Dalal R, Khatri R, et al Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743. PubMedAbstract available
HSIEH HC, Chen CC, Chou PH, Liu WC, et al Induction of neutralizing antibodies and mucosal IgA through intranasal
immunization with the receptor binding domain of SARS-CoV-2 spike protein fused
with the type IIb E. coli heat-labile enterotoxin A subunit.
Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752. PubMedAbstract available
SU WC, Chen ZY, Chang YS, Jeng KS, et al Functional assessments of SARS-CoV-2 single-round infectious particles with
variant-specific spike proteins on infectivity, drug sensitivity, and antibody
neutralization.
Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744. PubMedAbstract available
KIM DG, Kim U, Park IH, Ryu B, et al A bivalent form of a RBD-specific synthetic antibody effectively neutralizes
SARS-CoV-2 variants.
Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738. PubMedAbstract available
LUGANINI A, Sibille G, Pavan M, Mello Grand M, et al Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against
respiratory syncytial virus replication.
Antiviral Res. 2023;219:105734. PubMedAbstract available
October 2023
DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of
diverse viruses including SARS-CoV2.
Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736. PubMedAbstract available
PALLA SR, Li CW, Chao TL, Lo HV, et al Synthesis, evaluation, and mechanism of
1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent
reversible SARS-CoV-2 entry inhibitors.
Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735. PubMedAbstract available
KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731. PubMedAbstract available
September 2023
GAO R, Pascua PNQ, Nguyen HT, Chesnokov A, et al New insights into the neuraminidase-mediated hemagglutination activity of
influenza A(H3N2) viruses.
Antiviral Res. 2023;218:105719. PubMedAbstract available
BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2
polymerase.
Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716. PubMedAbstract available
August 2023
IVASHCHENKO AA, Jones JC, Shkil DO, Ivanenkov YA, et al Resistance profiles for the investigational neuraminidase inhibitor AV5080 in
influenza A and B viruses.
Antiviral Res. 2023;217:105701. PubMedAbstract available
VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin
binding.
Antiviral Res. 2023;217:105700. PubMedAbstract available
CORONA A, Madia VN, De Santis R, Manelfi C, et al Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
Antiviral Res. 2023;217:105697. PubMedAbstract available
July 2023
NGUYEN HT, Chesnokov A, De La Cruz J, Pascua PNQ, et al Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza
A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679. PubMedAbstract available
SPENGLER JR, Carter K, Delang L, Durantel D, et al Meeting report: 36th international conference on antiviral research in Lyon,
France, March 13-17, 2023.
Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678. PubMedAbstract available
SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the
expression and release of type I interferons upon activation of the host's immune
response.
Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676. PubMedAbstract available
BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677. PubMedAbstract available
TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al Assessment of the frequency of SARS-CoV-2 Omicron variant escape from
RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
Antiviral Res. 2023;216:105671. PubMedAbstract available
JEONG JH, Choi JH, Kim BK, Min SC, et al Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and
broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669. PubMedAbstract available
FENG Y, Yang Y, Zou S, Qiu S, et al Identification of alpha-linolenic acid as a broad-spectrum antiviral against
zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666. PubMedAbstract available
June 2023
MU S, Zou X, Wang Y, Deng X, et al The combined effect of oseltamivir and favipiravir on influenza a virus evolution
in patients hospitalized with severe influenza.
Antiviral Res. 2023 Jun 25:105657. doi: 10.1016/j.antiviral.2023.105657. PubMedAbstract available
CAI H, Yan J, Liu S, Li P, et al Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659. PubMedAbstract available
MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2
infection.
Antiviral Res. 2023;216:105655. PubMedAbstract available
JUNG HE, Ku KB, Kang BH, Park JH, et al Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified
spike protein and a genetic adjuvant confers lasting mucosal immunity against
SARS-CoV-2.
Antiviral Res. 2023;216:105656. PubMedAbstract available
CHANG YJ, Le UNP, Liu JJ, Li SR, et al Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively
reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2
and MERS-CoV.
Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653. PubMedAbstract available
ZHANG J, Nian X, Liu B, Zhang Z, et al Development of MDCK-based quadrivalent split seasonal influenza virus vaccine
with high safety and immunoprotection: A preclinical study.
Antiviral Res. 2023;216:105639. PubMedAbstract available
May 2023
WU CY, Kao SE, Tseng YC, Lin YP, et al Pilot-scale production of inactivated monoglycosylated split H(1)N(1) influenza
virus vaccine provides cross-strain protection against influenza viruses.
Antiviral Res. 2023 May 30:105640. doi: 10.1016/j.antiviral.2023.105640. PubMedAbstract available
WANG X, Lin L, Chen Z, Si W, et al Mutations at site 207 of influenza a virus NS1 protein switch its function in
regulating RIG-I-like receptors mediated antiviral responses.
Antiviral Res. 2023 May 23:105641. doi: 10.1016/j.antiviral.2023.105641. PubMedAbstract available
DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster
model.
Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638. PubMedAbstract available
HUANG X, Fan W, Sun J, Yang J, et al SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be
ameliorated by ACE inhibitor Captopril.
Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636. PubMedAbstract available
HU J, Zhang L, Zheng X, Wang G, et al Long noncoding RNA #61 exerts a broad anti-influenza a virus effect by its long
arm rings.
Antiviral Res. 2023 May 15:105637. doi: 10.1016/j.antiviral.2023.105637. PubMedAbstract available
YANG X, Long F, Jia W, Zhang M, et al Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced
ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export.
Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635. PubMedAbstract available
April 2023
CHO J, Shin Y, Yang JS, Kim JW, et al Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron
subvariants.
Antiviral Res. 2023;214:105609. PubMedAbstract available
LI Y, Wang K, Sun H, Wu S, et al Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases
cathepsin L and TMPRSS2.
Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606. PubMedAbstract available
CONG Y, Lee JH, Perry DL, Cooper K, et al Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography
with computed tomography as a measure of COVID-19 severity in the aged, young,
and humanized ACE2 SARS-CoV-2 hamster models.
Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605. PubMedAbstract available
March 2023
SON S, Ahn SB, Kim G, Jang Y, et al Identification of broad-spectrum neutralizing antibodies against influenza A
virus and evaluation of their prophylactic efficacy in mice.
Antiviral Res. 2023;213:105591. PubMedAbstract available
BILLS C, Xie X, Shi PY The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
Antiviral Res. 2023;213:105590. PubMedAbstract available
CONG Y, Mucker EM, Perry DL, Dixit S, et al Evaluation of a panel of therapeutic antibody clinical candidates for efficacy
against SARS-CoV-2 in Syrian hamsters.
Antiviral Res. 2023;213:105589. PubMedAbstract available
YANG Y, Cao L, Yan M, Zhou J, et al Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against
coronaviruses including SARS-CoV-2.
Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586. PubMedAbstract available
VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to
assess the fusogenic potential of spike mutants.
Antiviral Res. 2023;213:105587. PubMedAbstract available
DICHTL S, Diem G, Jager M, Zaderer V, et al Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex
vivo, but fail to reduce tissue inflammation.
Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581. PubMedAbstract available
ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized
mouse model.
Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580. PubMedAbstract available
LU C, Zhang Y, Liu X, Hou F, et al Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants
following an inactivated whole-virus vaccine.
Antiviral Res. 2023;212:105556. PubMedAbstract available
KIM JW, Heo K, Kim HJ, Yoo Y, et al Novel bispecific human antibody platform specifically targeting a fully open
spike conformation potently neutralizes multiple SARS-CoV-2 variants.
Antiviral Res. 2023;212:105576. PubMedAbstract available
SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks
for old dogs.
Antiviral Res. 2023;212:105575. PubMedAbstract available
ISSMAIL L, Ramsbeck D, Jager C, Henning T, et al Identification and evaluation of a novel tribenzamide derivative as an inhibitor
targeting the entry of the respiratory syncytial virus.
Antiviral Res. 2023;211:105547. PubMedAbstract available
HU Y, Zhu Y, Yu Y, Liu N, et al Design and characterization of novel SARS-CoV-2 fusion inhibitors with
N-terminally extended HR2 peptides.
Antiviral Res. 2023;212:105571. PubMedAbstract available
February 2023
XIAO Y, Yan Y, Chang L, Ji H, et al CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating
SKP2 dependent ACE2 degradation.
Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558. PubMedAbstract available
LI J, Wang Y, Solanki K, Atre R, et al Nirmatrelvir exerts distinct antiviral potency against different human
coronaviruses.
Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555. PubMedAbstract available
MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host
cells.
Antiviral Res. 2023;211:105550. PubMedAbstract available
January 2023
ZHU Y, Li M, Liu N, Wu T, et al Development of highly effective LCB1-based lipopeptides targeting the spike
receptor-binding motif of SARS-CoV-2.
Antiviral Res. 2023;211:105541. PubMedAbstract available
BASILE A, Zannella C, De Marco M, Sanna G, et al Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2
monoclonal antibody.
Antiviral Res. 2023;211:105546. PubMedAbstract available
December 2022
SPENGLER JR, Welch SR, Deval J, Gentry BG, et al Meeting report: 35th international conference on antiviral research in Seattle,
WA, USA - March 21-25, 2022.
Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521. PubMedAbstract available